RevolutionLogo.png
Revolution Medicines to Participate in Upcoming Investor Conferences
February 02, 2023 07:00 ET | Revolution Medicines, Inc.
REDWOOD CITY, Calif., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today...
RevolutionLogo.png
Revolution Medicines to Present at 41st Annual J.P. Morgan Healthcare Conference
January 03, 2023 07:00 ET | Revolution Medicines, Inc.
REDWOOD CITY, Calif., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today...
RevolutionLogo.png
Revolution Medicines Announces Publication Describing Design and Synthesis of RMC-5552, a First-in-Class, Bi-Steric mTORC1-Selective Inhibitor
December 19, 2022 07:00 ET | Revolution Medicines, Inc.
Findings Published in the Journal of Medicinal Chemistry Demonstrate Compound’s Exceptional Selectivity for mTORC1 over mTORC2 Tumor Regressions Observed During Combination Treatment with a Bi-Steric...
RevolutionLogo.png
Revolution Medicines to Regain Global Rights to RMC-4630 following Sanofi’s Termination of SHP2 Inhibitor Development and Commercialization Collaboration
December 07, 2022 16:05 ET | Revolution Medicines, Inc.
REDWOOD CITY, Calif., Dec. 07, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today...
RevolutionLogo.png
Revolution Medicines to Participate in Upcoming Investor Conferences
November 09, 2022 16:05 ET | Revolution Medicines, Inc.
REDWOOD CITY, Calif., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today...
Cyclacel Pharmaceuticals logo
Cyclacel Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update
November 09, 2022 16:05 ET | Cyclacel
- Oral Fadraciclib Daily Dosing Well Tolerated in 18 Evaluable Patients Treated in Dose-Escalation of Phase 1/2 Trial in Advanced Solid Tumors and Lymphoma - - Two Partial Responses in Lymphoma and...
RevolutionLogo.png
Revolution Medicines Reports Third Quarter 2022 Financial Results and Update on Corporate Progress
November 07, 2022 16:05 ET | Revolution Medicines, Inc.
Dose escalation ongoing in Phase 1/1b trials evaluating two RAS(ON) Inhibitor drug candidates, RMC-6236 (RASMULTI inhibitor) and RMC-6291 (KRASG12C inhibitor) Completed successful equity financing to...
RevolutionLogo.png
Revolution Medicines to Report Financial Results for Third Quarter 2022 After Market Close on November 7, 2022
November 01, 2022 16:05 ET | Revolution Medicines, Inc.
REDWOOD CITY, Calif., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers,...
Hookipa Pharma Logo Square.png
HOOKIPA announces strategic collaboration and license agreement with Roche to develop novel arenaviral immunotherapy for KRAS-mutated cancers
October 20, 2022 07:00 ET | HOOKIPA Pharma Inc.
Roche to receive license for HOOKIPA’s HB-700 program and option to license a second undisclosed novel arenaviral immunotherapyHOOKIPA to receive $25 million in upfront cash as well as potential...
RevolutionLogo.png
Revolution Medicines Doses First Patient in Phase 1/1b Clinical Trial of RMC-6291, Company’s First Mutant-Selective RAS(ON) Inhibitor
September 22, 2022 07:00 ET | Revolution Medicines, Inc.
KRASG12C(ON) Inhibitor with highly differentiated mechanism of action being evaluated in patients with cancers harboring KRASG12C mutation RMC-6291 is first mutant-selective RAS(ON) Inhibitor to...